Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

Rhea-AI Summary

Brickell Biotech, Inc. (NASDAQ: BBI) announced it will report its second quarter financial results on August 11, 2022. Management will host a conference call and webcast at 4:30 p.m. EDT to discuss these results and recent corporate highlights. Interested parties can join the call at 1-844-826-3035 (U.S.) or through the live audio webcast on Brickell’s website. The company focuses on developing innovative therapeutics for autoimmune and inflammatory diseases, leveraging extensive industry experience in product development and commercialization.

Positive

• Plans to report second quarter financial results on August 11, 2022.
• Management's extensive experience in product development and global commercialization.

Negative

• None.

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11^th. Brickell’s management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights.

To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conference ID number: 10168280. To access the live audio webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website for approximately 90 days.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Brickell’s pipeline consists of several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm® and Pluvicto®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that Brickell believes can meaningfully benefit patients who are suffering from chronic, debilitating diseases that are underserved by available therapies. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

FAQ

What are Brickell Biotech's upcoming financial reporting dates?

Brickell Biotech will report its second quarter financial results on August 11, 2022.

What time is Brickell Biotech's conference call for financial results?

The conference call will take place at 4:30 p.m. EDT on August 11, 2022.

Where can I access the webcast for Brickell Biotech's financial results?

The live audio webcast can be accessed on Brickell's website under the Investors section.

What does Brickell Biotech focus on in its business strategy?

Brickell Biotech focuses on developing innovative therapeutics for autoimmune and inflammatory diseases.

What is the stock symbol for Brickell Biotech?

The stock symbol for Brickell Biotech is BBI.